GlycoMimetics, Inc. (GLYC)
After hours:
| Previous close | 2.1600 |
| Open | 2.1700 |
| Bid | 1.9100 x 300 |
| Ask | 1.9600 x 200 |
| Day's range | 1.8800 - 2.1700 |
| 52-week range | 1.1100 - 3.5300 |
| Volume | |
| Avg. volume | 408,417 |
| Market cap | 124.067M |
| Beta (5Y monthly) | 2.19 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023
ROCKVILLE, Md., March 27, 2024--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today reported its financial results and highlights for the quarter and year ended December 31, 2023. Cash and cash equivalents as of December 31, 2023, were $41.8 million.
- Business Wire
GlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024
ROCKVILLE, Md., March 13, 2024--GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report fourth quarter and 2023 full year financial results on Wednesday, March 27, 2024 at 8:30 a.m. ET.
- Business Wire
GlycoMimetics to Participate in Upcoming Cowen 44th Annual Health Care Conference
ROCKVILLE, Md., February 26, 2024--GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that Harout Semerjian, Chief Executive Officer, will participate in the Leukemia Panel at the Cowen 44th Annual Health Care Conference in Boston, MA on Monday, March 4, 2024 at 12:50 p.m. ET.
